Abivax’s lead drug shows strong late-stage results for ulcerative colitis, and the company now has enough cash runway to focus on getting it approved and launched. A simple-to-take treatment and possible interest from a bigger drug company could change how investors see it.Read more

After a rocky early launch, Iovance now has a cancer treatment already cleared for use, and the story shifts from “will it work?” to “can it catch on” as more hospitals come on board and manufacturing improves. If results in other hard-to-treat cancers hold up, the company could grow far beyond melanoma—and it may even draw interest from a bigger drugmaker looking to fill future gaps.Read more